摘要
目的探讨联合应用雷贝拉唑、铝碳酸镁和莫沙比利治疗难治性胃食管反流病(rGERD)的临床疗效。方法将202例rGERD患者随机分为A(n=72)、B(n=68)和C组(n=62),分别采用雷贝拉唑+铝碳酸镁+莫沙比利、雷贝拉唑+莫沙比利及铝碳酸镁+莫沙比利治疗。4及8周后评价临床症状,8周后评价内镜下有效率。结果治疗4周后,A、B和C组患者临床症状总改善率分别为88.9%、79.4%和61.3%,A组与B、C组相比差异显著(χ2=7.3531,P<0.05)。治疗8周后,A、B和C组患者临床症状总改善率分别为97.2%、88.2%和71.0%,内镜下有效率分别为94.4%、85.3%和67.7%,A组临床症状总改善率和内镜下有效率与B、C组相比存在显著性差异(χ2=9.6079,P<0.01;χ2=8.6496,P<0.05)。结论雷贝拉唑联合铝碳酸镁和莫沙比利治疗rGERD有良好的临床疗效。
Objective To evaluate the effect of rabeprazole combined with hydrotalcite and mosapride on refractory gastroesophageal reflux disease（rGERD）. Methods A total of 202 rGERD patients were randomly divided into group A（ n =72）, B（ n=68 ）and C （ n = 62 ）, treated with rabeprazole plus hydrotalcite plus mosapride, rabeprazole plus mosapride, and hydrotacite plus mosapride, respectively. The clinical outcomes were observed and analyzed after 4 and 8 weeks of treatment. Endoscopy was performed to evaluate the effective rate in the three groups. Results After 4 weeks of treatment, the total improvement rate was significantly higher in group A（88.9% ） than that in group B（79.4） and C（61.3） （X2 =-7. 3531, P 〈0. 05） o 8 weeks later,the total improvement rates were 97.2% ,88.2% and 71.0% in group A,B arid C,and the effective rates detected by endoscopy were 94. 4% ,85.3% and 67. 7%, respectively. The total improvement rate（ X2 = 9. 6039, P 〈 0. 01 ）and effective rate（ X2 = 8. 6496, P 〈 0. 05 ） were markedly higher in group A than those in B and C group. Conclusion Rabeprazole combined with hydrotalcite and mosapride may be highly effective in the treatment of rGERD.
出处
《临床消化病杂志》
2009年第1期49-51,共3页
Chinese Journal of Clinical Gastroenterology
关键词
胃食管反流病
雷贝拉唑
铝碳酸镁
莫沙比利
Gastroesophageal reflux disease
Rabeprazole
Hydrotalcite
Mosapride
